KRW 3710.0
(-2.62%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 69.96 Billion KRW | -26.04% |
2022 | 94.6 Billion KRW | 22.45% |
2021 | 77.25 Billion KRW | 14.69% |
2020 | 67.36 Billion KRW | 6.94% |
2019 | 62.99 Billion KRW | 8.64% |
2018 | 57.98 Billion KRW | 2.59% |
2017 | 56.51 Billion KRW | 11.99% |
2016 | 50.46 Billion KRW | 19.85% |
2015 | 42.1 Billion KRW | -1.18% |
2014 | 42.6 Billion KRW | 0.99% |
2013 | 42.19 Billion KRW | -15.98% |
2012 | 50.21 Billion KRW | 25.47% |
2011 | 40.02 Billion KRW | 4.02% |
2010 | 38.47 Billion KRW | -7.66% |
2009 | 41.66 Billion KRW | 9.45% |
2008 | 38.07 Billion KRW | 82.74% |
2007 | 20.83 Billion KRW | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 72.86 Billion KRW | 4.15% |
2024 Q3 | 72.12 Billion KRW | -5.32% |
2024 Q2 | 76.17 Billion KRW | 4.54% |
2023 Q2 | 76.69 Billion KRW | -17.57% |
2023 Q1 | 93.03 Billion KRW | -1.66% |
2023 FY | 69.96 Billion KRW | -26.04% |
2023 Q4 | 69.96 Billion KRW | -4.36% |
2023 Q3 | 73.15 Billion KRW | -4.61% |
2022 Q2 | 93.37 Billion KRW | 27.69% |
2022 Q3 | 89.57 Billion KRW | -4.07% |
2022 FY | 94.6 Billion KRW | 22.45% |
2022 Q4 | 94.6 Billion KRW | 5.61% |
2022 Q1 | 73.12 Billion KRW | -5.35% |
2021 Q2 | 84.02 Billion KRW | 24.81% |
2021 Q3 | 85.03 Billion KRW | 1.21% |
2021 Q4 | 77.25 Billion KRW | -9.15% |
2021 FY | 77.25 Billion KRW | 14.69% |
2021 Q1 | 67.32 Billion KRW | -0.06% |
2020 Q4 | 67.36 Billion KRW | -2.73% |
2020 FY | 67.36 Billion KRW | 6.94% |
2020 Q3 | 69.25 Billion KRW | 1.1% |
2020 Q2 | 68.49 Billion KRW | 15.96% |
2020 Q1 | 59.07 Billion KRW | -6.22% |
2019 Q3 | 60.22 Billion KRW | 2.11% |
2019 Q1 | 57.08 Billion KRW | -1.54% |
2019 Q2 | 58.98 Billion KRW | 3.33% |
2019 Q4 | 62.99 Billion KRW | 4.59% |
2019 FY | 62.99 Billion KRW | 8.64% |
2018 Q1 | 50.43 Billion KRW | -10.76% |
2018 FY | 57.98 Billion KRW | 2.59% |
2018 Q4 | 57.98 Billion KRW | 14.73% |
2018 Q3 | 50.53 Billion KRW | -1.41% |
2018 Q2 | 51.26 Billion KRW | 1.63% |
2017 Q2 | 58.49 Billion KRW | 13.36% |
2017 FY | 56.51 Billion KRW | 11.99% |
2017 Q4 | 56.51 Billion KRW | 1.01% |
2017 Q3 | 55.95 Billion KRW | -4.34% |
2017 Q1 | 51.59 Billion KRW | 2.24% |
2016 Q1 | 43.78 Billion KRW | 4.0% |
2016 FY | 50.46 Billion KRW | 19.85% |
2016 Q3 | 49.39 Billion KRW | -1.61% |
2016 Q4 | 50.46 Billion KRW | 2.18% |
2016 Q2 | 50.19 Billion KRW | 14.64% |
2015 Q3 | 44.52 Billion KRW | -1.72% |
2015 Q2 | 45.3 Billion KRW | -1.65% |
2015 Q1 | 46.06 Billion KRW | 8.11% |
2015 FY | 42.1 Billion KRW | -1.18% |
2015 Q4 | 42.1 Billion KRW | -5.43% |
2014 FY | 42.6 Billion KRW | 0.99% |
2014 Q4 | 42.6 Billion KRW | -5.16% |
2014 Q3 | 44.92 Billion KRW | 3.82% |
2014 Q1 | 40.55 Billion KRW | -3.88% |
2014 Q2 | 43.27 Billion KRW | 6.7% |
2013 Q3 | 49.16 Billion KRW | 3.84% |
2013 FY | 42.19 Billion KRW | -15.98% |
2013 Q4 | 42.19 Billion KRW | -14.18% |
2013 Q1 | 47.87 Billion KRW | -4.66% |
2013 Q2 | 47.34 Billion KRW | -1.11% |
2012 Q4 | 50.21 Billion KRW | 0.0% |
2012 Q1 | 45.92 Billion KRW | 14.74% |
2012 FY | 50.21 Billion KRW | 25.47% |
2011 FY | 40.02 Billion KRW | 4.02% |
2011 Q4 | 40.02 Billion KRW | 1.36% |
2011 Q3 | 39.48 Billion KRW | -4.02% |
2011 Q2 | 41.14 Billion KRW | 5.22% |
2011 Q1 | 39.1 Billion KRW | 1.62% |
2010 Q4 | 38.47 Billion KRW | -8.75% |
2010 Q1 | 42.05 Billion KRW | 0.93% |
2010 Q3 | 42.16 Billion KRW | -9.99% |
2010 FY | 38.47 Billion KRW | -7.66% |
2010 Q2 | 46.84 Billion KRW | 11.39% |
2009 Q2 | 45.46 Billion KRW | 29.71% |
2009 Q4 | 41.66 Billion KRW | -7.59% |
2009 Q3 | 45.09 Billion KRW | -0.83% |
2009 Q1 | 35.05 Billion KRW | -7.93% |
2009 FY | 41.66 Billion KRW | 9.45% |
2008 Q2 | 34.54 Billion KRW | 14.22% |
2008 Q3 | 37.88 Billion KRW | 9.66% |
2008 Q1 | 30.24 Billion KRW | 45.16% |
2008 FY | 38.07 Billion KRW | 82.74% |
2008 Q4 | 38.07 Billion KRW | 0.5% |
2007 Q2 | 21.49 Billion KRW | 4.23% |
2007 Q3 | 23.76 Billion KRW | 10.56% |
2007 Q1 | 20.61 Billion KRW | 0.0% |
2007 FY | 20.83 Billion KRW | 0.0% |
2007 Q4 | 20.83 Billion KRW | -12.33% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Yuyu Pharma, Inc. | 77.85 Billion KRW | 10.134% |
Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 92.475% |
Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 90.105% |
HANDOK Inc. | 449.7 Billion KRW | 84.441% |
Kukje Pharma Co., Ltd. | 85.67 Billion KRW | 18.329% |
Yuhan Corporation | 712.33 Billion KRW | 90.178% |
Dong-A ST Co., Ltd. | 631.91 Billion KRW | 88.928% |
SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -340.201% |
Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 91.786% |
Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -30.711% |
Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 66.015% |
Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | 6.922% |
MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | 52.659% |
Hana Pharm Co., Ltd. | 70.4 Billion KRW | 0.616% |
Yuyu Pharma, Inc. | 77.85 Billion KRW | 10.134% |
Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -92.028% |
REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 72.141% |
Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 68.298% |
JW Holdings Corporation | 827.51 Billion KRW | 91.545% |
Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 83.989% |
Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 88.076% |
JW Pharmaceutical Corporation | 379.59 Billion KRW | 81.568% |
Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 11.77% |
Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 71.189% |
Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 78.817% |
Yuyu Pharma, Inc. | 77.85 Billion KRW | 10.134% |
Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 85.721% |
Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 91.846% |
JW Pharmaceutical Corporation | 379.59 Billion KRW | 81.568% |
Yuhan Corporation | 712.33 Billion KRW | 90.178% |
Jeil Pharma Holdings Inc | 477.81 Billion KRW | 85.357% |
Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | 48.917% |
Suheung Co., Ltd. | 516.66 Billion KRW | 86.458% |
JW Pharmaceutical Corporation | 379.59 Billion KRW | 81.568% |
Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | 54.724% |
Korea United Pharm Inc. | 89.96 Billion KRW | 22.228% |
CKD Bio Corp. | 170.76 Billion KRW | 59.026% |
Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 71.293% |
Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 55.62% |
Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -62.643% |
Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 11.77% |
Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 88.938% |
Boryung Corporation | 373.1 Billion KRW | 81.247% |
Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 66.394% |
Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 66.015% |
JW Lifescience Corporation | 96.44 Billion KRW | 27.452% |